Insulin glargine (Toujeo) vs UBT38006
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin glargine (Toujeo)
Marketed by Sanofi
NCT01499082 · Phase 3 · completed
The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.
Reported efficacy
Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)
Result source: NCT01499082
UBT38006
Developed by United Bio-Technology (Hengqin)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin glargine (Toujeo) | UBT38006 |
|---|---|---|
| HbA1c, change | —Not reported | —Not reported |
| Body weight, change (kg) | —Not reported | —Not reported |
| HbA1c below 7% | —Not reported | —Not reported |
| Fasting plasma glucose, change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
HbA1c, change
- Insulin glargine (Toujeo)
- —Not reported
- UBT38006
- —Not reported
Body weight, change (kg)
- Insulin glargine (Toujeo)
- —Not reported
- UBT38006
- —Not reported
HbA1c below 7%
- Insulin glargine (Toujeo)
- —Not reported
- UBT38006
- —Not reported
Fasting plasma glucose, change
- Insulin glargine (Toujeo)
- —Not reported
- UBT38006
- —Not reported
3-point MACE (% with event)
- Insulin glargine (Toujeo)
- —Not reported
- UBT38006
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
UBT38006: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Insulin glargine (Toujeo): 4 of 4 rows · UBT38006: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin glargine (Toujeo) |
|---|---|
| Dropout rate | 14.8%a NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result14.9% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result2.6% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 19.4%a NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result9.8% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | a trauma 3.7% cough 0.9% gastroparesis 0.9% NCT03013985 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin glargine (Toujeo)
show 6 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin glargine (Toujeo)'s landscape · UBT38006's landscape